ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Compugen Ltd

Compugen Ltd (CGEN)

1.82
-0.05
(-2.67%)
Closed July 20 4:00PM
1.815
-0.005
(-0.27%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.82
Bid
0.55
Ask
2.97
Volume
277,708
1.75 Day's Range 1.90
0.53 52 Week Range 3.0301
Market Cap
Previous Close
1.87
Open
1.90
Last Trade
5
@
1.82
Last Trade Time
Financial Volume
$ 499,356
VWAP
1.7981
Average Volume (3m)
358,680
Shares Outstanding
86,620,000
Dividend Yield
-
PE Ratio
-8.36
Earnings Per Share (EPS)
-0.22
Revenue
33.46M
Net Profit
-18.75M

About Compugen Ltd

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immu... Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Computer Software/svcs Diverse
Website
Headquarters
Holon, Center, Isr
Founded
1993
Compugen Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGEN. The last closing price for Compugen was $1.87. Over the last year, Compugen shares have traded in a share price range of $ 0.53 to $ 3.0301.

Compugen currently has 86,620,000 shares outstanding. The market capitalization of Compugen is $161.98 million. Compugen has a price to earnings ratio (PE ratio) of -8.36.

CGEN Latest News

Compugen to Present at Upcoming Antibody Industrial Symposium

Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel, June 17, 2024 HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a...

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire HOLON, Israel, May 30, 2024 Phase 3 trial evaluating...

Compugen Reports First Quarter 2024 Results

Compugen Reports First Quarter 2024 Results PR Newswire HOLON, Israel, May 20, 2024 Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant...

U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip

U.S. index futures showed a slight uptick in Monday’s pre-market, buoyed by the Dow Jones closing above the significant 40,000 point mark for the first time the previous week. At 6:16 AM...

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential PR Newswire HOLON, Israel, May 16, 2024 HOLON, Israel, May 16, 2024 /PRNewswire/...

Compugen Appoints David Silberman as Chief Financial Officer

Compugen Appoints David Silberman as Chief Financial Officer PR Newswire HOLON, Israel, May 15, 2024 HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a...

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 PR Newswire HOLON, ISRAEL, May 6, 2024 HOLON, ISRAEL, May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-0.5464480874321.832.051.753761571.87118633CS
4-0.04-2.150537634411.862.051.53069561.77906173CS
12-0.07-3.70370370371.892.551.53586802.04546255CS
26-0.13-6.666666666671.953.03011.54771452.29659481CS
520.5846.77419354841.243.03010.539362581.93398067CS
156-4.94-73.07692307696.767.480.518722612.5469765CS
260-1.59-46.62756598243.4119.90.519260646.6401391CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
226.82M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
217.11M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
188.2M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M

CGEN Discussion

View Posts
Monksdream Monksdream 2 weeks ago
CGEN under $2
👍️0
midastouch017 midastouch017 1 month ago
Compugen to Present at Upcoming Antibody Industrial Symposium

https://finance.yahoo.com/news/compugen-present-upcoming-antibody-industrial-110000879.html

HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France.

Event: 12th Antibody Industrial Symposium, Montpellier, France
Date: Friday, June 21, 2024
Presenter: Pierre Ferré, Ph.D., SVP, Preclinical Development and Corporate Operations, Compugen
Presentation title: Case study on clinical dose selection for TIGIT monospecific and bispecific antibodies
👍️0
midastouch017 midastouch017 2 months ago
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

https://finance.yahoo.com/news/compugen-receive-milestone-payment-triggered-110000791.html

Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer

Broadening the assessment of rilvegostomig reinforces Compugen's partnering strategy to expand opportunities for its pipeline

Compugen to receive $5 million milestone payment from AstraZeneca

HOLON, Israel, May 30, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. Both rilvegostomig and COM902 are designed to have reduced Fc effector function.

The trial, called TROPION-Lung10, is evaluating the efficacy and safety of rilvegostomig as monotherapy and in combination with datopotamab deruxtecan (Dato-DXd), AstraZeneca and Daiichi Sankyo's (TSE: 4568) TROP2-directed antibody drug conjugate versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high PD-L1 expression (TC = 50%) and without actionable genomic alterations. The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo and is expected to enrol approximately 675 patients in more than 14 countries. Further details about TROPION-Lung10 are available on ClinicalTrials.gov, identifier: NCT06357533.

"We are very excited to see the advancement of rilvegostomig into its second Phase 3 trial by AstraZeneca in collaboration with Daiichi Sankyo, two global leaders in oncology," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "TROPION-Lung10 follows the start of the ARTEMIDE-Biliary01 Phase 3 trial evaluating rilvegostomig in biliary tract cancer, for which we received a $10 million milestone payment. Now, after dosing the first patient in this lung cancer trial, we are eligible to receive a $5 million milestone payment from AstraZeneca. Broadening the assessment of rilvegostomig reinforces our partnering strategy to expand opportunities for our pipeline and brings us closer to realizing potential future milestone payments and royalties."

The ARTEMIDE-Biliary01 Phase 3 trial is evaluating the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in patients with biliary tract cancer after surgical resection with curative intent. Further details about the ARTEMIDE-Biliary01 trial are available on ClinicalTrials.gov, identifier: NCT06109779.

About the Compugen-AstraZeneca license agreement

In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen's monospecific antibodies that bind to TIGIT, including COM902, for the development of bispecific and multispecific antibody products, excluding such bispecific and multispecific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. Compugen has received $35.5 million in upfront and milestone payments to date and is eligible to receive an additional $5 million milestone payment as described in this press release. Compugen is eligible to receive up to an aggregate milestone amount of $200 million in development and regulatory milestones for the first and second indications for the first product and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional bi- or multi-specific products are developed based on Compugen's monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.

Rilvegostomig (previously AZD2936) is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902. Rilvegostomig is in Phase 3 development by AstraZeneca through this license agreement. Both rilvegostomig and COM902 are designed to have reduced Fc effector function to avoid depletion of CD8+ T cells.
👍️0
Monksdream Monksdream 2 months ago
CGEN under $3
👍️0
Monksdream Monksdream 3 months ago
CGEN under $2
👍️0
Monksdream Monksdream 4 months ago
CGEN new 52 week hi
👍️0
Monksdream Monksdream 5 months ago
CGEN 10Q
👍️0
midastouch017 midastouch017 6 months ago
Nice market reaction:
1.9100+0.1600 (+9.1429%)
As of 01:21PM EST. Market open.
👍️0
midastouch017 midastouch017 6 months ago
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

https://finance.yahoo.com/news/compugen-receive-10-million-milestone-120500521.html

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.

"I am delighted to see the advancement of the rilvegostomig Phase 3 trial by AstraZeneca, a global leader in oncology, which has dosed the first patient triggering a $10 million milestone payment to Compugen," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "Our license agreement with AstraZeneca is part of our strategy to broaden commercialization opportunities for our pipeline and specifically capitalize on the potentially emerging promise of bispecific therapies while maintaining our focus on the development of COM902 as part of the combination with COM701, our potential first-in-class anti-PVRIG antibody."

About the Compugen-AstraZeneca license agreement

In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen's monospecific antibodies that bind to TIGIT, including COM902, for the development of bispecific and multispecific antibody products, excluding such bispecific and multispecific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. In addition to the $10 million milestone payment described in this press release, Compugen has received a $10 million upfront payment, and an additional $15.5 million in milestone payments to date, all out of up to an aggregate milestone amount of $200 million that the Company is eligible to receive in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional bi- or multi-specific therapies are developed based on Compugen's monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.

Further details about ARTEMIDE-Bil01 trial are available on ClinicalTrials.gov, identifier: NCT06109779

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements relating to the recruitment of subjects to the ARTEMIDE-Bil01 trial. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen's approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value; and the general market, political and economic conditions in the countries in which Compugen operates, including Israel; and the effect of the evolving nature of the recent war in Gaza between Israel and Hamas. These risks and other risks are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:

Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071



Cision
Cision
View original content:https://www.prnewswire.com/news-releases/compugen-to-receive-10-million-milestone-payment-following-dosing-of-first-patient-in-astrazeneca-phase-3-rilvegostomig-trial-in-biliary-tract-cancer-302028318.html

SOURCE Compugen
👍️0
midastouch017 midastouch017 6 months ago
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

https://finance.yahoo.com/news/compugen-regains-compliance-nasdaq-minimum-120000043.html

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

As announced on November 3, 2023, the Company was notified that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company's ordinary shares needed to be at least $1.00 for a minimum of 10 consecutive business days.

The Notification Letter confirmed that the Company evidenced a closing bid price at or greater than the $1.00 per ordinary share minimum requirement for the last 10 consecutive business days from December 19, 2023 to January 3, 2024 and that the Company has regained compliance with the Minimum Bid Price Requirement.
👍️0
stock1ace1 stock1ace1 7 months ago
Easy $ cgen down another -3% today
👍️0
TheFinalCD TheFinalCD 7 months ago
When you warn traders not to short that crazy stock… but they just have to…#tradingIsEasy pic.twitter.com/rTDwQ4MR3a— Modern_Rock (@modern_rock) December 19, 2023
👍️0
KOmani KOmani 7 months ago
Nah.

Pharma is horrible to hold on a risk reward basis through waiting for news.

The stock is selling off as someone is trying to get shares.

Once they get what they want, it will start bouncing.

There are a lot people that held and are up.

Easy to scare them out dropping from $2.50 to below $2.00

Today's deal sounds good, it's just that someone tried to get cheap shares.

It's best to find an entry on pullbacks on good pharma news because there is plenty to shakeout.

It's finding support for a push later.
👍️0
stock1ace1 stock1ace1 7 months ago
Short it gap fill
👍️0
tw0122 tw0122 7 months ago
CGEN hope for $1.67 new temp support previous resistance if not $1.46 if not $1.34 is a harder support level also
👍️0
TheFinalCD TheFinalCD 7 months ago
dilution tracker Major Developments
12/19/2023, 8:13:40 AM Gilead to Make $60 Million Upfront Payment and $30 Million in a Near Term Milestone Payment with a Total Deal Value of up to $848 Million

https://dilutiontracker.com/app/search/CGEN?a=dbb88c

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca
HOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN),
👍️0
TheFinalCD TheFinalCD 7 months ago
congrat$$$$

https://www.prnewswire.com/news-releases/compugen-will-be-eligible-to-receive-10-million-milestone-payment-upon-dosing-of-first-patient-in-astrazeneca-phase-3-rilvegostomig-trial-in-biliary-tract-cancer-302018835.html

https://finviz.com/quote.ashx?t=CGEN&ty=c&ta=1&p=d



https://dilutiontracker.com/app/search/CGEN?a=dbb88c
👍️0
CanuckCa$h CanuckCa$h 7 months ago
Conference call just started.
https://veidan.activetrail.biz/compugencorporateupdate19.12.23?action=thankyou
👍️0
midastouch017 midastouch017 7 months ago
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

https://finance.yahoo.com/news/compugen-host-conference-call-discuss-120500402.html

Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement

HOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to treat multiple tumor types.

Conference Call Details

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.

Following the live webcast, a replay will be available on the Company's website.
👍️0
midastouch017 midastouch017 7 months ago
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca

HOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.

"I am delighted to see the advancement of rilvegostomig into Phase 3 by AstraZeneca, a global leader in oncology," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "I believe that the progress of the rilvegostomig clinical program in this Phase 3 trial along with the Phase 1 and 2 trials in additional indications, demonstrates the commitment to explore the potential of this bispecific antibody, where the TIGIT component is derived from our anti-TIGIT antibody COM902."

About the Compugen-AstraZeneca license agreement

In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen's monospecific antibodies that bind to TIGIT, including COM902, for the development of bispecific and multispecific antibody products, excluding such bispecific and multispecific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. In addition to the $10 million milestone payment described here which Compugen will be eligible to receive on dosing of the first patient in the Phase 3 ARTEMIDE-Bil01 trial, Compugen has received a $10 million upfront payment, and an additional $15.5 million in milestone payments to date, all out of up to an aggregate milestone amount of $200 million that the Company is eligible to receive in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional bi- or multi-specific products are developed based on Compugen's monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.

Further details about ARTEMIDE-Bil01 trial are available on ClinicalTrials.gov, identifier: NCT06109779.
👍️0
midastouch017 midastouch017 7 months ago
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

https://finance.yahoo.com/news/gilead-compugen-announce-exclusive-license-120000324.html

– Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types –

– Gilead to Make $60 Million Upfront Payment and $30 Million in a Near Term Milestone Payment with a Total Deal Value of up to $848 Million –

FOSTER CITY, Calif. & HOLON, Israel, December 19, 2023--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218814564/en/

Compugen utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing natural IL-18 in the tumor microenvironment and inhibiting cancer growth.

"We are very pleased to add COM503 to our pipeline of investigational immuno-oncology therapies that have the potential to transform care for patients with cancer," said Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences. "We believe that this collaboration complements our strategy of developing modalities which promote immune-mediated tumor killing and may enable new combination therapies with programs in our growing oncology portfolio."

"We are delighted to enter into this collaboration with Gilead and believe that Gilead’s confidence in our differentiated approach to harness cytokine biology for cancer therapeutics speaks to the quality of our computational discovery capabilities as well as our ability to translate our novel discoveries into investigational drugs in the clinic and we look forward to working together to bring new treatment options to patients," said Anat Cohen-Dayag, Ph.D., President, and CEO at Compugen. "IL-18 is one of the rare cytokines which is naturally inhibited by an endogenous binding protein, presenting a unique opportunity to use a blocking antibody to increase the local concentrations of IL-18 within the tumor where it can potentiate anti-tumor immune responses, thereby potentially overcoming the limitations of systemically administered cytokines."

Terms of the Partnership

Under the terms of the agreement, Compugen will be responsible for the ongoing pre-clinical development and the future Phase 1 study of COM503. Thereafter, Gilead will have the sole right to develop and commercialize COM503.

Gilead will make Compugen an upfront payment of $60 million and $30 million in a near term milestone payment subject to IND clearance of COM503 expected in 2024. Compugen will also be eligible to receive up to an additional $758 million in future development, regulatory and commercial milestone payments, with a total deal value of $848 million. Compugen will also be eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales.

Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Compugen is expected to reduce Gilead’s GAAP and non-GAAP 2023 EPS by approximately $0.03 - $0.05.
👍️0
Awl416 Awl416 7 months ago
Wild
👍️0
Awl416 Awl416 7 months ago
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
👍️0
Master Stocktrader Master Stocktrader 11 months ago
News coming?
👍️0
turning stone turning stone 11 months ago
Bought almost 8000 shares today have very high hopes for this stock.
👍️0
Gusher405 Gusher405 2 years ago
Bump
👍️0
J.D. Penny J.D. Penny 3 years ago
I’ll be the first to admit I was wrong about where I saw the market value going for cgen. It appears that the horse is very strong with great lineage but it’s being ridden by a sub par jockey.
👍️0
J.D. Penny J.D. Penny 3 years ago
I feel like the pps settles @ $7-$9 until late 3rd early 4th Q. Then we see $5 or $40. Please be $40.
👍️0
J.D. Penny J.D. Penny 3 years ago
Per my boy Wang, “I figured why cgen has gotten smacked in the last week. So ark funds. The cathie wood fund that started this whole craze owns 29% of cgen. They had record outflows this week so they were forced to sell some stock. Ark was the firm that bought tesla when it was $100 and said it was going to $2000. They also own a huge chunk of BIDU. Stock fell from 350 to 280 this past week (similar selling to cgen)”

“Ark still owns a ton of cgen in all their different funds. Everything they invest in is next generation technology.”
👍️0
rainbowbudland rainbowbudland 3 years ago
Trump Covid?
it's the Chinese Virus.

:)
👍️0
J.D. Penny J.D. Penny 4 years ago
The new rating couldn’t have been timed worse. Jefferies and it’s analyst look foolish
👍️0
J.D. Penny J.D. Penny 4 years ago
New Analyst Rating---Jeffries puts a $25 target and buyout of CGEN imminent

Compugen assumed with a Buy at Jefferies Jefferies analyst Chris Howerton assumed coverage of Compugen with a Buy rating with a price target of $25, up from the firm's previous target of $20. The company's lead assets, alphaPVRIG and alphaTIGIT, are novel anti-cancer/immune-checkpoint drugs with evidence that supports pathways for broad tumor types, suggesting each drug could become "Keytruda-like," Howerton tells investors.

Read more at:
https://thefly.com/n.php?id=3174816
👍️0
J.D. Penny J.D. Penny 4 years ago
Recovered nicely from Trump Covid market reaction. Looking forward to positive test results any day now!
👍️0
LEGEND1266 LEGEND1266 4 years ago
Decided to take a position today as it was pushing through the 16's. Looks promising as a long term hold. GLTA
👍️0
J.D. Penny J.D. Penny 4 years ago
"Compugen’s (CGEN) early-stage study is evaluating the safety, tolerability and preliminary antitumor activity of COM701 (the company’s first-in-class anti-PVRIG antibody) in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) and BMS-986207."

https://finance.yahoo.com/news/compugen-starts-dosing-early-stage-053529308.html


I can see CGEN at $60-$75 per share min next year if a buyout occurs. I know a lot of heavy hitters are watching this and a working partnership with Bristol Myers Squibb, a 140 billion dollar beast is very encouraging.
👍️0
Alpine600 Alpine600 4 years ago
New closing high at $19.45. Hopefully we will see $20 soon. Market cap is starting to get pretty significant.
👍️0
J.D. Penny J.D. Penny 4 years ago
All I have to say is wow!! This could really be a life changer. I really believe this could be a $60-80 stock in a year.
👍️0
J.D. Penny J.D. Penny 4 years ago
Wall Street rumors scaring some weak hands. CGEN could bounce really fast with next patient test results. CGEN also being courted for a buyout by this time next year.
👍️0
Tempy Tempy 4 years ago
Great day here! Think we may finally be getting out of the trading channel we’ve been stuck in...
👍️0
J.D. Penny J.D. Penny 4 years ago
Compugen is the company everyone in Pharma will be talking about this year. Already a 7 plus bagger and climbing from its 52 week low.
👍️0
J.D. Penny J.D. Penny 4 years ago
Would love to see an updated CGEN chart. So much going on leading to next week's big conference.
👍️0
J.D. Penny J.D. Penny 4 years ago
Compugen initiated with a Buy at Roth Capital Roth Capital analyst Tony Butler initiated coverage of Compugen with a Buy rating and $28 price target. The company has discovered and is developing immune checkpoint therapeutic drugs to address the unmet needs in a multitude of cancer indications, Butler tells investors in a research note. Compugen's lead asset COM701, combined with the second asset COM902, has shown evidence of efficacy in tumors that are immunologically "cold," or immune-suppressed, where currently approved checkpoint inhibitors have shown little or no efficacy, contend the analyst.

Read more at:
https://thefly.com/landingPageNews.php?id=3076556
👍️0
Tempy Tempy 4 years ago
Roth Capital just gave a price target of $28...BOOM!!!
👍️0
J.D. Penny J.D. Penny 4 years ago
Big report coming out on April 27th!! Market knows this company is a monster in the making.
👍️0
ClarkKant ClarkKant 4 years ago
$CGEN ramping up for the presentation and buyout rumors it seems.

Hit $14 in AH last evening.
👍️0
J.D. Penny J.D. Penny 4 years ago
In a way I’m glad pps is down. Even w Covid 19 the stick was rising prior to dilution. CGEN will survive and do great things. You want to invest in crap or a company that cures cancer?
👍️0
ClayTrader ClayTrader 4 years ago
* * $CGEN Video Chart 03-10-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
J.D. Penny J.D. Penny 4 years ago
Test confirmed no toxic effects to patients and in many cases complete tumor reduction. Mic drop..sit back and watch this one sky rocket!
👍️0
ClayTrader ClayTrader 4 years ago
* * $CGEN Video Chart 02-06-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
J.D. Penny J.D. Penny 4 years ago
Over $9.00 boom
👍️0

Your Recent History

Delayed Upgrade Clock